Summary of Alumis Virtual KOL Event Company and Industry Overview - **Company**: Alumis - **Industry**: Dermatology, specifically focusing on psoriasis treatment Core Points and Arguments 1. **Introduction of Envudeucitinib**: The event highlighted the next-generation TYK2 inhibitor, envudeucitinib, and its significance in treating psoriasis, emphasizing its potential as a leading treatment option [3][4][5] 2. **Phase III Data Presentation**: Dr. Andrew Blauvelt presented the phase III data, showcasing the drug's efficacy, safety, and patient-reported outcomes, which were well-received at the American Academy of Dermatology Congress [2][9][46] 3. **Efficacy Metrics**: - Envudeucitinib demonstrated leading PASI 100 skin clearance rates of approximately 39.5% to 41% at week 24, indicating a significant improvement in skin condition [23][41] - The drug also showed a PASI 90 rate of about 65%, suggesting that two-thirds of patients achieved clear or almost clear skin [24][41] 4. **Quality of Life Improvements**: Significant reductions in itch scores were reported, with average scores dropping from 6 to around 1.7, indicating a dramatic improvement in patient comfort [33][41] 5. **Safety Profile**: The safety data indicated a favorable profile with low rates of serious adverse events, no concerning signals related to lab abnormalities, malignancies, or serious infections [38][41][46] 6. **Market Potential**: The psoriasis market is expected to grow significantly, with a need for effective oral treatments as patients often prefer pills over injections [5][44] Additional Important Content 1. **Patient Demographics**: The study included a robust population with about 10% of patients over 65 years old, indicating the drug's applicability across different age groups [17][18] 2. **Comparison with Competitors**: Envudeucitinib was compared favorably against apremilast, showing significantly better efficacy in skin clearance [20][21] 3. **Future Developments**: Plans for a once-a-day formulation and testing in younger populations were mentioned, indicating ongoing development and potential market expansion [42][55] 4. **Regulatory Considerations**: Discussions around the potential need for TB testing were addressed, with the company expressing confidence in the safety profile of envudeucitinib [61][62] 5. **Broader Indications**: Alumis is exploring the use of TYK2 inhibition for other conditions beyond psoriasis, including lupus and other interferon-driven diseases, indicating a strategic expansion of their product pipeline [55][57] This summary encapsulates the key points discussed during the Alumis Virtual KOL Event, focusing on the promising data surrounding envudeucitinib and its implications for the treatment of psoriasis and beyond.

Core Insights - Alumis Inc. reported positive Phase 3 topline results for envudeucitinib, showing significant skin clearance and symptom improvement in moderate-to-severe plaque psoriasis, along with a favorable safety profile [1][2] - The company plans to submit a New Drug Application (NDA) for envudeucitinib in the second half of 2026 [1] - Anticipated pivotal Phase 2b clinical data for envudeucitinib in systemic lupus erythematosus (SLE) is expected in the third quarter of 2026 [1][7] - Alumis completed a public offering, raising approximately $345.1 million in gross proceeds in January 2026 [1][5] Phase 3 Clinical Trials - The Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib met all primary and secondary endpoints with high statistical significance [5] - Approximately 65% of patients achieved a Psoriasis Area Severity Index (PASI) 90, and over 40% achieved PASI 100 at Week 24 [5] - The drug demonstrated a favorable safety and tolerability profile consistent with earlier Phase 2 results [5] Financial Performance - For the year ended December 31, 2025, Alumis reported total revenue of $24.05 million, primarily from license and collaboration revenue [15] - Research and development expenses increased to $386.0 million from $265.6 million in 2024, driven by clinical trial costs and increased headcount [12][15] - The net loss for 2025 was $243.3 million, an improvement from a net loss of $294.2 million in 2024 [12][15] Pipeline and Future Plans - Alumis is evaluating additional indications for envudeucitinib beyond psoriasis and SLE, as part of a unified TYK2 franchise development strategy [2][5] - An update on the TYK2 franchise strategy, including the timing for commencing A-005's Phase 2 trial, is expected in the second quarter of 2026 [5][8] - The company plans to present additional Phase 3 data at the American Academy of Dermatology (AAD) Annual Meeting in March 2026 [11]

Core Insights - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [3] Company Overview - Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including envudeucitinib for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases [3] - The company also has lonigutamab, an anti–insulin-like growth factor 1 receptor therapy for thyroid eye disease, along with several preclinical programs [3] Upcoming Events - Martin Babler, President and CEO of Alumis, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 9, 2026, at 10:40 a.m. ET [1] - A live webcast of the event will be available on the Alumis website, with a replay archived for 90 days [2]

Summary of Alumis Conference Call Company Overview - **Company**: Alumis - **Event**: Oppenheimer's Annual Healthcare Conference - **Key Speakers**: Martin Babler (CEO), John Schroer (CFO) Core Industry and Product Insights Psoriasis Treatment - **Product**: Envudeucitinib - **Phase 3 Data**: Positive top-line results announced in January - **Primary Endpoint Results**: - PASI 75: Average of 74% - sPGA 0/1: Average of 59% at week 16 [3][4] - **Secondary Results**: - PASI 90: Approximately 65% at week 24 - PASI 100: Just over 40% on average [5] - **Safety Profile**: Consistent with Phase II results; common side effects include headaches, upper respiratory infections, and acne. No malignancy signals observed [6][15][19]. Competitive Landscape - **Competitors**: J&J's IL-23 blocker and Takeda's TYK2 inhibitors - **Market Positioning**: Emphasis on the unique benefits of the TYK2 pathway, including improved patient-reported outcomes and quality of life [7][9]. - **Dosing Preference**: Market research indicates a preference for a twice-daily dosing regimen without food effects over a once-daily regimen with fasting requirements [11][12]. Regulatory and Commercial Plans - **NDA Submission**: Planned for the second half of the year, contingent on 48-week data [25]. - **Commercial Strategy**: Strong plan in place, with considerations for potential partnerships due to the broad indication landscape [26]. Future Opportunities Systemic Lupus Erythematosus (SLE) - **Unmet Need**: High demand for effective oral treatments; current approved drugs have low efficacy [27]. - **Ongoing Trial**: Phase 2b trial with over 400 patients, primary endpoint BICLA, results expected in Q3 [28]. - **Execution Strategy**: Focus on patient selection and managing co-medications to minimize placebo rates [30]. Pipeline Developments - **Lonigutamab**: Ongoing evaluation of its mechanism and competitive landscape; potential for CNS indications [39][41]. - **CNS Penetrant TYK2**: Consideration of broader applications beyond CNS [39]. Additional Considerations - **Malignancy Concerns**: No significant malignancy signals observed; background rates of cancer in trials acknowledged [18][21]. - **FDA Guidance**: Recent communications suggest potential for single trial approvals, which could impact SLE trial strategy [35][36]. This summary encapsulates the key points discussed during the conference call, highlighting Alumis's strategic positioning, product developments, and future opportunities in the healthcare market.

Summary of Alumis Conference Call Company Overview - **Company**: Alumis - **Industry**: Precision Immunology, specifically focusing on psoriasis and other autoimmune diseases Key Points and Arguments Financial and Operational Highlights - Alumis has a strong balance sheet with over **$630 million** in cash, providing runway into the **fourth quarter of 2027** [91] - The company is preparing for a potential NDA filing in the **second half of 2023** [37] Clinical Development - **Envudeucitinib**: Phase 3 results in psoriasis show: - **PASI 75** at week 24 is in the **70s%** - **PASI 90** and **PASI 100** rates are approximately **65%** and **40%**, respectively [3] - Fast onset of action with separation of PASI scores observed as early as week 4 [3] - Safety profile consistent with Phase II data, with no new safety signals [3] Market Dynamics - The oral drug market for psoriasis is expected to expand significantly, as **75%** of psoriasis patients prefer oral medications over injectables or topicals [27] - Current market dynamics indicate that the patient share of oral drugs is higher than that of injectables [25] - Alumis aims to position itself strongly in the oral psoriasis market, particularly for patients with scalp involvement and significant itch [31] Competitive Landscape - The company acknowledges competition from other TYK2 inhibitors, including **Sotyktu** and **Zasocitinib** from Takeda [22] - Alumis believes its product has a competitive edge in terms of efficacy and quality of life improvements [18] Future Indications and Research - Alumis is exploring additional indications beyond psoriasis, including **Systemic Lupus Erythematosus (SLE)** and other autoimmune diseases [46] - The company is conducting a pivotal Phase IIb trial for SLE, with results expected in the **third quarter of 2023** [52] - The potential for **20+ indications** is being considered, with a focus on optimizing the psoriasis indication and exploring rheumatology-related conditions [70] Strategic Partnerships - While Alumis has the capability to launch its products independently, the company is open to partnerships to optimize its TYK2 franchise across multiple indications [41][43] Conclusion - Alumis is positioned for significant growth in the precision immunology space, with promising clinical data and a strong financial foundation. The company is strategically preparing for market entry while exploring a broad pipeline of indications.

Company Overview - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [2] - The company utilizes a proprietary data analytics platform and precision approach to enhance patient health and outcomes [2] Product Pipeline - Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including envudeucitinib (formerly ESK-001), aimed at treating systemic immune-mediated disorders such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus [2] - The pipeline also features A-005 for neuroinflammatory and neurodegenerative diseases, and lonigutamab, a subcutaneously delivered therapy for thyroid eye disease [2] - Several preclinical programs have been identified through the company's precision approach [2] Investor Engagement - Alumis will participate in multiple investor conferences, including the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026 [4] - Live webcasts of these events will be accessible on the company's website, with replays archived for 90 days [1][4]

Group 1 - Alumis Inc. (NASDAQ:ALMS) has been recognized as a rising stock, with Chardan initiating coverage with a Buy rating and a price target of $37, driven by the potential of its late-stage autoimmune pipeline, particularly the drug envudeucitinib [1] - Envudeucitinib, a TYK2 inhibitor, has successfully met all primary and secondary endpoints in two Phase III trials for moderate-to-severe plaque psoriasis, demonstrating high statistical significance in skin clearance and patient-reported outcomes [1] - H.C. Wainwright has increased its price target for Alumis to $40 from $20, citing reduced regulatory failure risk and a higher projected revenue ceiling following the successful Phase 3 data [2] Group 2 - Morgan Stanley raised its price target for Alumis to $33 from $22, reflecting increased optimism about the drug's performance in treating moderate-to-severe plaque psoriasis, with the probability of success for this indication now at 80% [3] - Alumis is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for autoimmune disorders, previously known as Esker Therapeutics [4]

Core Insights - The transaction indicates a significant insider purchase by Srinivas Akkaraju, Director of Alumis, acquiring 588,235 shares for approximately $10.0 million, reflecting a strong belief in the company's future performance [5][6]. Company Overview - Alumis is a clinical-stage biotechnology company focused on developing therapies for autoimmune and neuroinflammatory diseases, leveraging advanced TYK2 inhibitor technology to address unmet medical needs [7]. Transaction Details - The shares were purchased at $17.00 each, which is below recent market prices, suggesting a favorable entry point for the insider [2][6]. - This acquisition is one of the largest recorded for Akkaraju, increasing his cumulative indirect holdings by nearly 47% in a single transaction [4][5]. Market Performance - Alumis' stock has appreciated significantly, with a 206.29% increase over the past year and over 400% in the last three months, indicating strong market confidence [5][8]. - The company recently reported successful phase 3 trial results for envudeucitinib, showing that 65% of patients achieved a 90% or better improvement in psoriasis severity scores [9]. Competitive Landscape - Alumis' psoriasis treatment candidate appears to be more effective than Amgen's Otezla, which had 33% of patients achieving a 75% improvement in similar trials [10].

Core Insights - Alumis Inc. (NASDAQ:ALMS) is recognized as one of the top 14 booming stocks to buy currently, with HC Wainwright & Co. raising its price target from $20 to $40 while maintaining a Buy rating [1][2] Group 1: Trial Results and Drug Approval - The price target adjustment by HC Wainwright & Co. followed promising results from Phase 3 ONWARD1 and ONWARD2 trials, which evaluated the efficacy of envudeucitinib in patients with moderate to severe plaque psoriasis [2] - Both trials successfully achieved their primary and secondary endpoints, demonstrating safe usage and tolerability among patients, who reported significant improvements in quality of life through reduced itching [3] - Alumis Inc. plans to file for FDA approval of envudeucitinib in the latter half of 2026 [3] Group 2: Market Expectations and Analyst Ratings - HC Wainwright & Co. believes the trial results have 'reset expectations' in the oral tyrosine kinase 2 (TYK2) area, indicating a strong likelihood of FDA approval for envudeucitinib, which could significantly boost the company's revenue [4] - Following the trial results, several research firms, including Wells Fargo and Morgan Stanley, have also revised their positions on Alumis Inc. by increasing their price targets [4] - As of January 12, Wall Street analysts have a consensus Strong Buy rating on the stock, with a one-year average share price target of $37.67, representing an upside of 78.62% [5] Group 3: Company Overview - Alumis Inc. is a biopharmaceutical company specializing in developing targeted therapies for immune-mediated diseases [5]

Company Overview - Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation targeted therapies for immune-mediated diseases [5] - The company utilizes a proprietary data analytics platform and precision approach to enhance patient health and outcomes [5] Recent Offering - Alumis announced the closing of an upsized underwritten public offering of 20,297,500 shares of common stock at a price of $17.00 per share, resulting in gross proceeds of approximately $345.1 million before deductions [1] - The offering included the full exercise of the underwriters' option to purchase an additional 2,647,500 shares [1] Underwriters - Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities served as joint book-running managers for the offering, while Baird and Oppenheimer & Co. acted as co-lead managers [2] Regulatory Compliance - The public offering was conducted under a shelf registration statement on Form S-3, which was previously filed and declared effective by the SEC on August 19, 2025 [3]